title: The risk of asthma exacerbation after stopping low-dose inhaled corticosteroids: a systematic review and meta-analysis of randomized controlled trials.
abstract: BACKGROUND
  Current asthma guidelines suggest that patients and their providers consider decreasing or stopping controller medications when asthma is stable.
  
  
  OBJECTIVE
  We sought to estimate the risk of asthma exacerbation in patients who stop low-dose inhaled corticosteroids (ICSs) compared with those who continue ICSs in randomized controlled trials.
  
  
  METHODS
  We identified relevant trials from a systematic review of English-language and non-English-language articles using MEDLINE, EMBASE, and CENTRAL (inception to January 21, 2012). Articles were screened at the abstract and full-text level by 2 independent reviewers. We included randomized controlled trials with a stable asthma run-in period of 4 weeks or more, an intervention to stop or continue ICSs, and a follow-up period of at least 3 months. We pooled results using a random-effects meta-analysis.
  
  
  RESULTS
  The search strategy identified 1798 potential articles, of which 172 were reviewed at the full-text level and 7 met the criteria for inclusion. The relative risk for an asthma exacerbation in patients who stopped ICSs compared with those who continued use was 2.35 (95% CI, 1.88-2.92; P < .001; I(2) = 0%), as determined by using data pooled from trials with a mean follow-up of 27 weeks. The pooled absolute risk difference for an asthma exacerbation was 0.23 (95% CI, 0.16-0.30; P < .001; I(2) = 44%). Patients who discontinued ICSs also had a decreased FEV1 of 130 mL (95% CI, 40-210 mL; P = .003; I(2) = 53%), a decreased mean morning peak expiratory flow of 18 L/min (95% CI, 6-29 L/min; P = .004; I(2) = 82%), and an increased mean standardized asthma symptom score of 0.43 SDs (95% CI, 0.28-0.58 SDs; P < .001; I(2) = 0%).
  
  
  CONCLUSIONS
  Patients with well-controlled asthma who stop regular use of low-dose ICSs have an increased risk of an asthma exacerbation compared with those who continue ICSs.
authors: Division of Allergic Diseases, Mayo Clinic, Rochester, MN 55905, USA. rank.matthew@mayo.edu
authors: Matthew A
authors: MA
authors: Rank
authors: John B
authors: JB
authors: Hagan
authors: Miguel A
authors: MA
authors: Park
authors: Jenna C
authors: JC
authors: Podjasek
authors: Shefali A
authors: SA
authors: Samant
authors: Gerald W
authors: GW
authors: Volcheck
authors: Patricia J
authors: PJ
authors: Erwin
authors: Colin P
authors: CP
authors: West
mesh_terms: D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage*; D000328:Adult; D000368:Aged; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage*; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D002648:Child; D006801:Humans; D010349:Patient Compliance; D012306:Risk; D055815:Young Adult
chemical_list: D000305:Adrenal Cortex Hormones; D018927:Anti-Asthmatic Agents